Back to 
UBS Group AG
UBS Group AG
NBRV3 quarters
Position history for UBS Group AG's holdings in NABRIVA THERAPEUTICS PLC
No. Ubs exited its NBRV (Nabriva Therapeutics) position in Q3 2022. Its Q2 2022 13F listed 31,663 shares worth $6,000. Ubs first reported NBRV in Q1 2022 and held it in 2 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$13,000
Total Shares Change
-30,781
Quarter-by-Quarter History
Other major holders of NBRV: FMR LLC, RENAISSANCE TECHNOLOGIES LLC